# Chahra Louafi

> Chahra Louafi is a Series A investor at Inserm Transfert Initiative backing Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Inserm Transfert Initiative](https://shizune.co/investors/profile/inserm-transfert-initiative)
- Location: Maisons-alfort, France
- Total investments: 5
- Last investment: Apr 2022
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/chahra-louafi/2/783/162

Chahra Louafi is a Series A investor at Inserm Transfert Initiative in Maisons-alfort focused on Biotechnology and Medical. Chahra Louafi is Director and Head of Investment Fund biotherapy and rare diseases Bpifrance (eg CDC Entreprises). Before joining CDC Entreprises in 2001, she was in charge of project development and entrepreneurship in a private incubator specializing in biotechnology. Within CDC Entreprises, attached to the New Developments Team, Chahra wasresponsible for investments in fund of funds dedicated to priming and technology transfer operations. She is Vice-President of the Supervisory Board of Inserm Transfert Initiative and member of the supervisory board of Cape Decisive Management. She serves on the governing bodies of DBV Technologies, Sensorion, Eyevensys, MEDday and Pixium Vision.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Therapeutics | 2 | 40% |
| Information Technology | 2 | 40% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Seed | 1 | 20% |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 3 | 60% |
| Switzerland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Implicity | Implicity is a developer of a Saas-based remote monitoring platform designed to provide smart monitoring of connected cardiac prostheses. The company's platform sorts and summarizes data of patients with connected pacemakers and defibrillators with the help of an artificial intelligence module and determines the criticality of each alerttaking into account the medical context of the patient, enabling cardiologists and healthcare professionals to automate the remote monitoring of their patients and get patients' telepulse on a single platform. | $23M | Series A | Apr 27, 2022 |  |
| Lucine | Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement andanalysis of the pain by facial, vocal and postural recognition. | $5.8M | Seed | Nov 18, 2020 |  |
| Therachon | Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel,Switzerland, with research labs in Nice, France. | $60M | Series B | Aug 09, 2018 |  |
| Therachon | Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel,Switzerland, with research labs in Nice, France. | $5M | Series A | Jan 06, 2017 |  |
| Sensorion | Sensorion, a Clapiers, France-based biopharmaceutical company specifically dedicated to the development of innovative and targeted therapeutic solutions to treat vestibular deficits. | $4.2M |  | Jan 21, 2015 |  |

5 of 5 investments shown.

## Co-investors
- [BNP Paribas Développement](https://shizune.co/investors/profile/bnp-paribas-developpement) — VC Fund, 2 deals together
- [Inserm Transfert Initiative](https://shizune.co/investors/profile/inserm-transfert-initiative) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [AQUITI Gestion](https://shizune.co/investors/profile/aquiti-gestion-aci) — VC Fund, 1 deal together
- [Crédit Mutuel Innovation](https://shizune.co/investors/profile/cm-cic-capital-innovation) — VC Fund, 1 deal together
- [Cowen Healthcare Investments](https://shizune.co/investors/profile/cowen-healthcare-investments) — VC Fund, 1 deal together

## About Inserm Transfert Initiative

VC Fund · Paris, France

Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.

2 contacts available at Inserm Transfert Initiative.

| Name | Title | Profile |
| --- | --- | --- |
| Jean-Michel Gauthier | CSO - Member of the Executive management Board (Directoire) | https://shizune.co/investors/profile/jean-michel-gauthier |
| Chahra Louafi | VP, Supervisory Board | https://shizune.co/investors/profile/chahra-louafi |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Chahra Louafi invest in?

Chahra Louafi invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chahra Louafi last invest?

The most recent investment recorded for Chahra Louafi closed in Apr 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co